Nader Sanai
@NaderSanai
Followers
2K
Following
632
Media
20
Statuses
227
@IvyBrainTumCtr Director. @BarrowNeuro Neurosurgical Oncologist. Leading an early-phase trials program to accelerate drug development for brain cancer.
Phoenix, AZ
Joined March 2019
What's new in the treatment of GBM? Great talk of @DrLombardiGiu in Bologna chaired by Emilie Le Rhun, Antonio Silvani and dr Sturiale.. looking at new trials with PARP inhibitor Niraparib and other new agents @EORTC @EANOassociation @NaderSanai @SapienzaRoma
0
3
20
That Dr. Spetzler flew in for this remains a source of personal pride. His legacy of inquiry, integrity, and leadership is a North Star for all of us.
#Neurosurgeon Dr. @NaderSanai, who directs the @IvyBrainTumCtr at Barrow, was presented with the 2024 #Arizona Bioscience Researcher of the Year award by #AZBio last week! Learn about Dr. Sanai's mission to defeat #braincancer in this @azbigmedia feature: https://t.co/paxPPBhoV0
9
1
54
So great to have three of @IvyBrainTumCtr researchers be part of this amazing @abta community. @AnChiTien @charutafurey and Artak Tovmasyan 👏🏻🧠
Exciting things are happening at the #ABTANationalConference! 🎉 Our amazing AARN members—leading brain tumor researchers—are here sharing groundbreaking ideas and innovations that bring us closer to finding a cure! 🙌💡🧠 #BrainTumorResearch #MeetHopeHeadOn #CureBrainTumors”
0
3
17
As we celebrate the approval of vorasidenib for treatment of grade II IDH-mutant, I would like to recognize those that developed the original compounds. See https://t.co/38HCJgegUc,
https://t.co/Clj7dXFGZW and perhaps most importantly https://t.co/AfN36y1TZP. Fantastic job!
pubs.acs.org
Optimization of a series of R132H IDH1 inhibitors from a high throughput screen led to the first potent molecules that show robust tumor 2-HG inhibition in a xenograft model. Compound 35 shows good...
4
23
85
Very inspiring talk by dr McDermott on Radiotherapy response and resistance of meningiomas at the International Neurosurgical Forum in Rome. Happy to see so many groups working on that @sahm_lab @LabRaleigh @EORTC @EANOassociation
0
4
17
GBM cell states are fluid, but manipulable
Happy to share results from a new Phase 0 trial led by @IvyBrainTumCtr @NaderSanai @smehtalab and @Kevin_C_Johnson: Single nucleus transcriptomics, PK/PD of combined CDK4/6 and mTOR inhibition in a phase 0/1 trial of recurrent high-grade glioma
1
4
22
❗🎉 We received FDA approval to proceed with our Phase 3 clinical trial in partnership w/ @GSK! We're accelerating the Gliofocus Study, a global trial comparing niraparib, a PARP1/2 inhibitor, against TMZ for newly diagnosed MGMT-unmethylated #GBM. 📰: https://t.co/OTBiobbIxw
4
12
54
Important point on the MoA of ADCs by Pat LoRusso. Radiolabeled antibody studies showed <1% of tumor uptake with antibody therapies. @VriesElisabeth
3
39
197
Excellent study … PARP trapping is key
We are happy to share our latest paper “A unified mechanism for PARP inhibitor-induced PARP1 chromatin retention at DNA damage sites in living cells”, out today in @CellReports. #PARP1 #PARPinhibitor #GenomicStability Hopefully not a boring thread ↓ https://t.co/MCU6BsbJRQ
0
0
5
Monday at #ASCO2024: Niraparib + XRT Phase 0/2 in Newly Diagnosed, MGMT-Unmethylated GBM OS= 20.3 months #Gliofocus Study coming in June: a global, label-enabling, @IvyBrainTumCtr-sponsored, head-to-head Phase 3 trial in partnership with @GSK
The Ivy Center announces Phase 0/2 clinical readout of niraparib indicating significant improvement in overall survival for newly diagnosed glioblastoma patients. Supported by @GSK, we are initiating a global, Phase 3 trial of niraparib. #ASCO24 📰: https://t.co/oFSecl7ppe
1
14
33
I'm sure no one needs reminding that #ASCO24 abstracts drop today at 5pm ET. Here's a reminder of the key presentations, though we won't see LBAs until the meeting itself https://t.co/pyFOgk0WZG $TNGX $MRUS $IDYA $AZN $JNJ
oncologypipeline.com
Abstract titles reveal some of ASCO’s key datasets.
1
12
36
FDA-ABTC workshop on drug permeability … candid takes (this from Bill Elmquist) and non-hyperbolic discourse. Worth the Baltimore redeye.
1
0
9
Survival Benefit Associated With Participation in Clinical Trials of Anticancer Drugs: A Systematic Review and Meta-analysis | Oncology | JAMA | JAMA Network
jamanetwork.com
This systematic review and meta-analysis examines whether patient participation in cancer trials is associated with greater survival benefit compared with routine care.
0
0
9
1535 PK/PD data in GBM at ASCO
Molecules of the Month – April 2024 Find out what compounds made our April 2024 Molecules of the Month list and check out recent articles for each. Article | https://t.co/0RmKQgWXfW
0
0
4